Status:
COMPLETED
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
Bayer
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biologica...
Detailed Description
Rationale: The drug combination called CHOP, or Cyclophosphamide (Cytoxan), Doxorubicin (Adriamycin), Vincristine (Oncovin), and Prednisone (Deltasone), has been used against different types of lympho...
Eligibility Criteria
Inclusion
- CD-20 Negative
- Previous treatment permitted: radiation, electron beam radiotherapy, PUVA, corticosteroids, IFN, low dose methotrexate, retinoids, Ontak
- CNS disease permitted
Exclusion
- Pregnant or Nursing
- prior Alemtuzumab
- history of active Hep C
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00323323
Start Date
March 1 2004
End Date
October 1 2016
Last Update
January 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210